[go: up one dir, main page]

WO2001077169A3 - Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides - Google Patents

Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides Download PDF

Info

Publication number
WO2001077169A3
WO2001077169A3 PCT/US2001/011208 US0111208W WO0177169A3 WO 2001077169 A3 WO2001077169 A3 WO 2001077169A3 US 0111208 W US0111208 W US 0111208W WO 0177169 A3 WO0177169 A3 WO 0177169A3
Authority
WO
WIPO (PCT)
Prior art keywords
polynucleotides
polypeptides
growth factor
stem cell
cell growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/011208
Other languages
French (fr)
Other versions
WO2001077169A9 (en
WO2001077169A2 (en
Inventor
Tom Y Tang
Ivan Labat
Radoje T Drmanac
Nancy K Mize
Mitsuo Nishikawa
Cheng-Chi Chao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kirin Brewery Co Ltd
Original Assignee
Kirin Brewery Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Brewery Co Ltd filed Critical Kirin Brewery Co Ltd
Priority to AU5904101A priority Critical patent/AU5904101A/en
Priority to CA002405104A priority patent/CA2405104A1/en
Priority to JP2001575639A priority patent/JP2003530124A/en
Priority to EP01932523A priority patent/EP1268543A2/en
Publication of WO2001077169A2 publication Critical patent/WO2001077169A2/en
Publication of WO2001077169A3 publication Critical patent/WO2001077169A3/en
Anticipated expiration legal-status Critical
Publication of WO2001077169A9 publication Critical patent/WO2001077169A9/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human stem cell growth factor-like protein. These polynucleotides comprise nucleic acid sequences isolated from cDNA libraries from human testis cells (Hyseq clone identification numbers 2880984 and 2881695, from human fetal skin (Hyseq clone identification number 15375176), adult spleen (Hyseq clone identification number 14856094), and human endothelial cells (Hyseq clone identification numbers 13804756, 13687487, 13804756). Other aspects of the invention include vectors containing processes for producing novel human stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides.
PCT/US2001/011208 2000-04-05 2001-04-05 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides Ceased WO2001077169A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU5904101A AU5904101A (en) 2000-04-05 2001-04-05 Methods and materials relating to novel stem cell growth factor-like polypeptides and polynucleotides
CA002405104A CA2405104A1 (en) 2000-04-05 2001-04-05 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
JP2001575639A JP2003530124A (en) 2000-04-05 2001-04-05 Methods and materials for novel stem cell growth factor-like polypeptides and polynucleotides
EP01932523A EP1268543A2 (en) 2000-04-05 2001-04-05 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US54377400A 2000-04-05 2000-04-05
US09/543,774 2000-04-05
US21573300P 2000-06-28 2000-06-28
US60/215,733 2000-06-28
US75756201A 2001-01-09 2001-01-09
US09/757,562 2001-01-09
US26661401P 2001-02-05 2001-02-05
US60/266,614 2001-02-05

Publications (3)

Publication Number Publication Date
WO2001077169A2 WO2001077169A2 (en) 2001-10-18
WO2001077169A3 true WO2001077169A3 (en) 2002-07-04
WO2001077169A9 WO2001077169A9 (en) 2002-12-19

Family

ID=27499020

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/011208 Ceased WO2001077169A2 (en) 2000-04-05 2001-04-05 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides

Country Status (5)

Country Link
EP (1) EP1268543A2 (en)
JP (1) JP2003530124A (en)
AU (1) AU5904101A (en)
CA (1) CA2405104A1 (en)
WO (1) WO2001077169A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411052B2 (en) 2001-03-05 2008-08-12 Nuvelo, Inc. Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
JP2005514917A (en) * 2001-10-03 2005-05-26 インサイト・ゲノミックス・インコーポレイテッド Secreted protein
ES2345256T3 (en) 2003-10-10 2010-09-20 Deutsches Krebsforschungszentrum COMPOSITIONS FOR DIAGNOSIS AND THERAPY OF DISEASES ASSOCIATED WITH ABERRANT EXPRESSION OF FUTRINAS (R-SPONDINAS) AND / OR WNT.
US20050256036A1 (en) 2004-01-27 2005-11-17 Boyle Bryan J Gastrointestinal proliferative factor and uses thereof
WO2007030290A2 (en) * 2005-09-07 2007-03-15 Maine Medical Center Research Cristin/r-spondin ligands active in the wnt signaling pathway and methods, compositions and kits relating thereto
EP1942926A4 (en) * 2005-10-07 2010-06-16 Nuvelo Inc SCFA1, PROTEIN OF THE STEM CELL FACTOR TYPE AND USES THEREOF
US7750124B2 (en) 2006-09-29 2010-07-06 Oncomed Pharmaceuticals, Inc. Anti-human DLL4 antibodies and compositions
DK2081586T4 (en) 2006-10-20 2019-01-21 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Rspondins as modulators of angiogenesis and vasculogenesis
WO2008075796A1 (en) * 2006-12-21 2008-06-26 Kyowa Hakko Kirin Co., Ltd. Agent for promoting recovery from blood cell depletion
PL3009148T3 (en) 2007-07-02 2019-03-29 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
DK2393917T3 (en) 2009-02-03 2016-04-18 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells comprising these ORGANOIDER AND STEM CELLS
WO2010121923A1 (en) 2009-04-15 2010-10-28 Deutsches Krebsforschungszentrum Rspondin-3 inhibition in bone disorders
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
CA2841745A1 (en) 2011-07-15 2013-01-24 Oncomed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
EP2827879B1 (en) 2012-03-21 2019-05-08 Dana-Farber Cancer Institute, Inc. Isolation and use of human lymphoid organ-derived suppressive stromal cells
KR20150036603A (en) 2012-07-13 2015-04-07 온코메드 파마슈티칼스, 인크. Rspo3 binding agents and uses thereof
CA2961374A1 (en) 2014-09-16 2016-03-24 Oncomed Pharmaceuticals, Inc. Treatment of fibrotic diseases
CN108607101A (en) * 2018-05-04 2018-10-02 广西中医药大学附属瑞康医院 Application of the ZIP1 genes in preparing the product for inhibiting apoptosis of mesenchymal stem cell
CN111420034A (en) * 2019-01-08 2020-07-17 上海莱馥医疗科技有限公司 Mixed stem cell preparation for treating psoriasis and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998049302A1 (en) * 1997-04-25 1998-11-05 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO2000056755A1 (en) * 1999-03-19 2000-09-28 Human Genome Sciences, Inc. 49 human secreted proteins
WO2001040294A1 (en) * 1999-11-29 2001-06-07 Bioroad Gene Development Ltd. Shanghai A novel polypeptide - human thrombospondin-30 and a polynucleoti de encoding the same
WO2001057190A2 (en) * 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998049302A1 (en) * 1997-04-25 1998-11-05 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO2000056755A1 (en) * 1999-03-19 2000-09-28 Human Genome Sciences, Inc. 49 human secreted proteins
WO2001040294A1 (en) * 1999-11-29 2001-06-07 Bioroad Gene Development Ltd. Shanghai A novel polypeptide - human thrombospondin-30 and a polynucleoti de encoding the same
WO2001057190A2 (en) * 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200142, Derwent World Patents Index; Class B04, AN 2001-397948, XP002183188 *
See also references of EP1268543A2 *
SZILVASSY S J ET AL: "LEUKEMIA INHIBITORY FACTOR UPREGULATES CYTOKINE EXPRESSION BY A MURINE STROMAL CELL LINE ENABLING THE MAINTENANCE OF HIGHLY ENRICHED COMPETITIVE REPOPULATING STEM CELLS", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 87, no. 11, 1 June 1996 (1996-06-01), pages 4618 - 4628, XP000971084, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
JP2003530124A (en) 2003-10-14
AU5904101A (en) 2001-10-23
WO2001077169A9 (en) 2002-12-19
CA2405104A1 (en) 2001-10-18
EP1268543A2 (en) 2003-01-02
WO2001077169A2 (en) 2001-10-18

Similar Documents

Publication Publication Date Title
WO2001077169A3 (en) Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
WO2001088092A3 (en) Methods and materials relating to stem cell factor-like (scf-like) polypeptides and polynucleotides
CA2253238A1 (en) Novel agouti-related gene
WO2000075350A3 (en) Nucleic acid sequences encoding proteins involved in fatty acid beta-oxidation and methods of use
WO2001055336A3 (en) Methods and materials relating to cd84-like polypeptides and polynucleotides
EP1624065A3 (en) Agarase and gene thereof
WO1997043409A3 (en) Method of providing novel dna sequences
CA2170515A1 (en) Nucleotide sequences for novel protein tyrosine phosphatases
WO2001053454A3 (en) Methods and materials relating to g protein-coupled receptor-like polypeptides and polynucleotides
WO2003029405A3 (en) Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
WO2001053500A8 (en) Methods and materials relating to stem cell growth factor-like poypeptides and polynucleotides
WO2001044276A3 (en) Moss genes from physcomitrella patens encoding proteins involved in the synthesis of tocopherols carotenoids and aromatic amino acids
WO2001031029A3 (en) Human sphingosine kinase gene
EP1574520A3 (en) Methods and materials relating to neuronal guidance molecule-like (NGM-like) polypeptides and polynucleotides
WO2001055335A3 (en) Methods and materials relating to leukocyte immunoglobulin receptor-like (lir-like) polypeptides and polynucleotides
WO1997002730A3 (en) Enamel matrix related polypeptide
WO2000004041A3 (en) Methods and molecules relating to cd39-like polypeptides
WO2001055332A3 (en) Methods and materials relating to novel growth regulatory-like polypeptides and polynucleotides
WO2001053456A3 (en) Methods and materials relating to prothrombinase-like polypeptides and polynucleotides
WO1999045107A8 (en) Novel calpain and dna encoding the same
WO2001057233A3 (en) Methods and materials relating to preadipocyte factor-1-like (pref-1-like) polypeptides and polynucleotides
WO2001075064A3 (en) Method and materials relating to insulin-like growth factor binding protein-like polypeptides and polynucleotides
WO2001055337A3 (en) Methods and materials relating to carcinoembryonic antigen-like (cea-like) polypeptides and polynucleotides
CA2284101A1 (en) Deoxynucleoside kinase from insect cells for the synthesis of nucleoside monophosphates
WO2001055435A3 (en) Methods and materials relating to hematopoietic cytokine-like polypeptides and polynucleotides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2405104

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 575639

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001932523

Country of ref document: EP

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGE 197, CLAIMS, REPLACED BY A NEW PAGE 197; PAGES 1/6-6/6, DRAWINGS, REPLACED BY NEW PAGES 1/6-6/6; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 2001932523

Country of ref document: EP